10-K: Creative Medical Technology Holdings Reports Full Year 2023 Results, Focuses on Clinical Trials and Platform Development

Creative Medical Technology Holdings reported its full year 2023 results, highlighting progress in clinical trials and platform development, while also noting a decrease in revenue from its commercial products.

Summary

• Creative Medical Technology Holdings, a biotechnology company, reported a net loss of $5.3 million for the year ended December 31, 2023, compared to a net loss of $10.1 million in 2022.
• The company's revenue decreased significantly to $9,000 in 2023 from $88,600 in 2022, primarily due to a decline in sales of CaverStem kits.
• Research and development expenses decreased to $1.97 million in 2023 from $6.27 million in 2022, due to a one-time $5 million expense in 2022 for research tools.
• The company had approximately $10 million in cash, certificates of deposit, and short-term U.S. Treasuries at the end of 2023.
• The company is focused on advancing its clinical trials for Type I Diabetes (CELZ-201 CREATE-1) and AlloStemSpine Chronic Lower Back Pain (CELZ-201 ADAPT), and developing its ImmCelz platform.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and platform development, the significant decrease in revenue and continued losses raise concerns. The company's reliance on future capital raises also adds uncertainty.

Positives

• The company has made significant progress in advancing its clinical trials, including FDA clearance for a Phase I/II trial for lower back pain.
• The company has developed a proprietary allogenic cell line (AlloStem) with a Master Cell Bank and Drug Master File.
• The company has reported positive results from its StemSpine and AlloStem (CELZ-201) studies.
• The company has successfully developed a human induced pluripotent stem cell (iPSC) line, which is expected to save time and expenses in research and development.
• The company has a robust intellectual property portfolio with four issued patents and fifty pending patent applications.

Negatives

• The company's revenue decreased significantly in 2023 compared to 2022.
• The company continues to incur significant operating losses.
• The company's commercial products, CaverStem and FemCelz, have generated minimal revenue.
• The company is dependent on third parties for manufacturing its commercial products.
• The company's autologous products are currently not eligible for reimbursement from public or private insurers.

Risks

• The company's future profitability is uncertain, and it may need to raise additional capital to fund its operations.
• The company's product candidates are subject to regulatory approvals and the risks inherent in the development of biopharmaceutical products.
• The company may not be successful in commercializing its proposed products and therapies.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company is subject to risks arising from the global outbreak of the COVID-19 coronavirus and the wars in Ukraine and the Gaza Strip.
• The company may not be able to protect its proprietary rights and could be subject to intellectual property suits.
• The company is dependent on its executive officers and may not be able to pursue its current business strategy effectively if they leave.
• The company's stock price is highly volatile, and investors could lose all or part of their investment.

Future Outlook

The company anticipates needing to raise additional capital in the future to support ongoing operations and clinical trials, and expects to continue raising capital through the sale of securities.

Management Comments

• Management is currently re-evaluating the marketing strategy for the Caverstem and FemCelz products.
• Management believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development.
• Management believes that the company will have sufficient cash to meet its anticipated operating costs and capital expenditure requirements through at least March 2025.

Industry Context

The company operates in the rapidly evolving field of regenerative medicine, facing competition from both established pharmaceutical companies and emerging biotech firms. The company's focus on cell-based therapies aligns with broader industry trends, but it must navigate regulatory hurdles and market acceptance challenges.

Comparison to Industry Standards

• The company's ImmCelz platform demonstrated a 75% reduction in required donor cells and a purity greater than 95%, which is better than industry standards of 80% purity.
• The company's StemSpine procedure has shown continued efficacy for treating chronic lower back pain, which is comparable to results from companies like Mesoblast Limited.
• The company's AlloStem (CELZ-201) treatment for Type 2 Diabetes showed a 93% efficacy in reducing insulin requirements, which is a significant result compared to standard medical therapies.
• The company's approach of injecting stem cells around the disc for lower back pain differs from companies like Mesoblast, Longeveron, BioRestorative Therapies, and DiscGenics, which inject directly into the disc.

Related Party Transactions

• The company purchased research tools for $5 million from Narkeshyo LLC, an entity affiliated with a former director and current consultant.
• The company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by a former director.
• The company acquired a patent from CMH, a related company, covering the use of various stem cells for the treatment of lower back pain.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential losses due to the company's volatile stock price.
• Employees are subject to the risks associated with the company's financial performance and potential restructuring.
• Patients may benefit from the company's development of new therapies, but also face the risks associated with clinical trials.
• Suppliers and creditors are subject to the company's ability to meet its financial obligations.

Next Steps

• The company plans to continue its clinical trials for Type I Diabetes (CELZ-201 CREATE-1) and AlloStemSpine Chronic Lower Back Pain (CELZ-201 ADAPT).
• The company will continue to develop its ImmCelz platform and file INDs for additional indications.
• The company is exploring options to achieve market penetration and product profitability for Caverstem and FemCelz products.
• The company is currently vetting Contract Research Organizations for a planned trial enrollment commencing in early 2024 for the AlloStemSpine (CELZ-201 ADAPT) trial.

Key Dates

Keywords

stem cell therapy, regenerative medicine, clinical trials, immunotherapy, Type 1 diabetes, lower back pain, erectile dysfunction, FDA approval, biotechnology, AlloStem, ImmCelz, iPSC